{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:57:12Z","timestamp":1791464232334,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ygyno.2022.08.020","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T22:52:09Z","timestamp":1663887129000},"page":"256-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer"],"prefix":"10.1016","volume":"167","author":[{"given":"Kadan","family":"Yfat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotait","family":"Mariam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beiner","family":"Mario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirte","family":"Hal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephy","family":"Dana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Lina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruchim","family":"Ilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pond","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helpman","family":"Limor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2022.08.020_bb0005","first-page":"11","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J. Clin."},{"issue":"March","key":"10.1016\/j.ygyno.2022.08.020_bb0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.critrevonc.2019.05.014","article-title":"Ovarian cancer relapse: from the latest scientific evidence to the best practice","volume":"140","author":"Luvero","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2022.08.020_bb0015","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1186\/s40064-016-2660-0","article-title":"Management of relapsed ovarian cancer: a review","volume":"5","author":"Giornelli","year":"2016","journal-title":"Springerplus."},{"key":"10.1016\/j.ygyno.2022.08.020_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-018-0424-x","article-title":"DNA damage repair in ovarian cancer: unlocking the heterogeneity","volume":"11","author":"Gee","year":"2018","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ygyno.2022.08.020_bb0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/OGX.0b013e31824b70b7","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"67","author":"Yang","year":"2012","journal-title":"Obstet. Gynecol. Surv."},{"issue":"3","key":"10.1016\/j.ygyno.2022.08.020_bb0030","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ygyno.2011.08.032","article-title":"A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer","volume":"123","author":"Adams","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2022.08.020_bb0035","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdq628","article-title":"Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients","volume":"22","author":"Vencken","year":"2011","journal-title":"Ann. Oncol."},{"issue":"21","key":"10.1016\/j.ygyno.2022.08.020_bb0040","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2022.08.020_bb0045","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2022.08.020_bb0050","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum- sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"issue":"10106","key":"10.1016\/j.ygyno.2022.08.020_bb0055","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.ygyno.2022.08.020_bb0060","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/1078155216657165","article-title":"An update on current and emerging therapies for epithelial ovarian cancer: focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis","volume":"23","author":"Chung","year":"2017","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.ygyno.2022.08.020_bb0065","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","article-title":"BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer","volume":"27","author":"Moschetta","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2022.08.020_bb0070","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ygyno.2010.03.014","article-title":"Hormone prevention strategies for breast, endometrial and ovarian cancers","volume":"118","author":"Rice","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.08.020_bb0075","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0090-8258(03)00152-5","article-title":"Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel","volume":"89","author":"Hirsh-Yechezkel","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2022.08.020_bb0080","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.fertnstert.2015.02.011","article-title":"Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers","volume":"103","author":"Perri","year":"2015","journal-title":"Fertil. Steril."},{"issue":"3","key":"10.1016\/j.ygyno.2022.08.020_bb0085","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ygyno.2012.03.006","article-title":"BRCA1\/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer","volume":"125","author":"Dann","year":"2012","journal-title":"Gynecol. Oncol. [Internet]"},{"issue":"3","key":"10.1016\/j.ygyno.2022.08.020_bb0090","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1158\/1078-0432.CCR-14-2497","article-title":"Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer","volume":"21","author":"Candido-dos-Reis","year":"2015","journal-title":"Clin. Cancer Res. [Internet]"},{"issue":"1","key":"10.1016\/j.ygyno.2022.08.020_bb0095","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/1078-0432.CCR-14-1816","article-title":"Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis","volume":"21","author":"Zhong","year":"2015","journal-title":"Clin. Cancer Res. [Internet]"},{"issue":"9","key":"10.1016\/j.ygyno.2022.08.020_bb0100","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2022.08.020_bb0105","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/ijgc-2019-000308","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"29","author":"Colombo","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2022.08.020_bb0110","series-title":"Original Reports Abstract Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer","first-page":"1","author":"Baek","year":"2022"},{"issue":"2","key":"10.1016\/j.ygyno.2022.08.020_bb0115","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","volume":"2013","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.ygyno.2022.08.020_bb0120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/OGX.0000000000000777","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"75","author":"Coleman","year":"2020","journal-title":"Obstet. Gynecol. Surv."},{"issue":"23","key":"10.1016\/j.ygyno.2022.08.020_bb0125","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl. J. Med. [Internet]"},{"issue":"4","key":"10.1016\/j.ygyno.2022.08.020_bb0130","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol. [Internet]"},{"issue":"12","key":"10.1016\/j.ygyno.2022.08.020_bb0135","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1245\/s10434-018-6700-6","article-title":"BRCA mutation status to personalize management of recurrent ovarian cancer: a multicenter study","volume":"25","author":"Marchetti","year":"2018","journal-title":"Ann. Surg. Oncol. [Internet]"},{"issue":"1","key":"10.1016\/j.ygyno.2022.08.020_bb0140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ijgo.12769","article-title":"Predictive factors of recurrence in patients with early-stage epithelial ovarian cancer","volume":"145","author":"Ditto","year":"2019","journal-title":"Int. J. Gynecol. Obstet [Internet]"},{"issue":"3","key":"10.1016\/j.ygyno.2022.08.020_bb0150","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ygyno.2021.10.008","article-title":"Gynecologic oncology secondary cytoreductive surgery for recurrent ovarian cancer : an SGO clinical practice statement","volume":"163","author":"Harrison","year":"2021","journal-title":"Gynecol. Oncol. [Internet]"},{"issue":"9","key":"10.1016\/j.ygyno.2022.08.020_bb0155","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer."},{"issue":"2","key":"10.1016\/j.ygyno.2022.08.020_bb0160","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","article-title":"A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection","volume":"19","author":"Tian","year":"2012","journal-title":"Ann. Surg. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2022.08.020_bb0165","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.08.020_bb0170","article-title":"Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse","volume":"221","author":"Hollis","year":"2019","journal-title":"Am. J. Obstet Gynecol. [Internet]"},{"issue":"7","key":"10.1016\/j.ygyno.2022.08.020_bb0175","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.ejso.2020.01.035","article-title":"Salvage lymphadenectomy in recurrent ovarian cancer patients: analysis of clinical outcome and BRCA1\/2 gene mutational status","volume":"46","author":"Gallotta","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2022.08.020_bb0180","series-title":"Cytoreductive Surgery followed by Chemotherapy and Olaparib Maintenance in BRCA 1 \/ 2 Mutated Recurrent Ovarian Cancer : A retrospective MITO Group Study","first-page":"1031","author":"Cecere","year":"2021"},{"issue":"9747","key":"10.1016\/j.ygyno.2022.08.020_bb0185","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822005741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822005741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:03:04Z","timestamp":1758772984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822005741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0090825822005741"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.08.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}